A non-controlled study conducted in Wuhan, China weighing the efficacy of IFN-α-2b in 77 patients found that the treatment led to a significant decline in viral load in the upper respiratory tract and in IL-6 and CRP levels [69], emphasizing the potential dual effect (anti-viral and anti-inflammatory) of this drug in the course of COVID-19 treatment. The gene discussed is IFNA1; the disease is COVID-19.